Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 6/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 6/20 | 0.39 |
| ▸ | BRAF | P15056 | 3/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Laflunimus SCHEMBL9234178 | 1.00 | DHODH (0.67) | DHODHLMNAKDRBRAFUSP30 | |
| Laflunimus SCHEMBL21132 | 1.00 | DHODH (0.67) | DHODHLMNAKDRBRAFUSP30 | |
| Laflunimus SCHEMBL29677348 | 1.00 | DHODH (0.67) | DHODHLMNAKDRBRAFUSP30 | |
| SCHEMBL17100730 | 0.86 | DHODH (0.49) | DHODHKDRBRAFUSP30EPHX2 | |
| SCHEMBL21539519 | 0.86 | DHODH (0.49) | DHODHKDRBRAFUSP30EPHX2 | |
| SCHEMBL15196662 | 0.86 | DHODH (0.62) | DHODHLMNAGAATP53MAPT | |
| SCHEMBL8717137 | 0.84 | DHODH (0.66) | DHODHLMNAGAATHRB | |
| SCHEMBL8717143 | 0.84 | DHODH (0.66) | DHODHLMNAGAATHRB | |
| SCHEMBL16274172 | 0.82 | DHODH (0.58) | DHODHGAATP53MAPTTHRB | |
| SCHEMBL28236310 | 0.81 | DHODH (0.49) | DHODHLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 626 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4362968-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD47-SIRPA THERAPEUTIC AGENT | Ohio State Innovation Foundation (US) | 2024-05-08 | — | — | EP | claimed |
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | OHIO STATE INNOVATION FOUNDATION (US) | 2023-09-28 | — | — | US | claimed |
| WO-2023278778-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD47-SIRPΑ THERAPEUTIC AGENT | OHIO STATE INNOVATION FOUNDATION (US) | 2023-01-05 | — | — | WO | claimed |
| CN-115551488-A | Nanoparticle compositions | 艾格埃克斯制药有限公司 | 2022-12-30 | — | — | CN | claimed |
| EP-4081219-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | Ohio State Innovation Foundation (US) | 2022-11-02 | — | — | EP | claimed |
| WO-2021134045-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | OHIO STATE INNOVATION FOUNDATION (US) | 2021-07-01 | — | — | WO | claimed |
| EP-3829578-A1 | SIROLIMUS CONTAINING COMPOSITIONS | CHEMISTRYRX (US) | 2021-06-09 | — | — | EP | claimed |
| US-20200069661-A1 | SIROLIMUS CONTAINING COMPOSITIONS | CHEMISTRYRX (US) | 2020-03-05 | — | — | US | claimed |
| WO-2020047342-A1 | SIROLIMUS CONTAINING COMPOSITIONS | CHEMISTRYRX (US) | 2020-03-05 | — | — | WO | claimed |
| US-9668972-B2 | Nonsteroidal immunomodulating kit and composition and uses thereof | FOAMIX PHARMACEUTICALS LTD. (IL) | 2017-06-06 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2008038147-A2 | FOAMABLE VEHICLE COMPRISING DICARBOXYLIC ACID OR DICARBOXYLIC ACID ESTER AND PHARMACEUTICAL COMPOSITIONS THEREOF | FOAMIX LTD. (US) | 2008-04-03 | — | — | WO | claimed |
| US-20080044444-A1 | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof | FOAMIX LTD. (IL) | 2008-02-21 | — | — | US | claimed |
| EP-1863447-A2 | NONSTEROIDAL IMMUNOMODULATING KIT AND COMPOSITION AND USES THEREOF | Foamix Ltd. (IL) | 2007-12-12 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| WO-2007007208-A2 | NONSTEROIDAL IMMUNOMODULATING KIT AND COMPOSITION AND USES THEREOF | FOAMIX LTD. (US) | 2007-01-18 | — | — | WO | claimed |
| US-20060193789-A1 | Surfacant, film forming agent, water, gas propellant; plant and animal extracts and oils; may include malathion | FOAMIX LTD. (IL) | 2006-08-31 | — | — | US | claimed |
| US-20050232869-A1 | Nonsteroidal immunomodulating kit and composition and uses thereof | FOAMIX LTD. | 2005-10-20 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | DHODH, CD38, DPYD | DHODH 1/4885LMNA 1972/4885KDR 3444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.